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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the eighth of a series of 16 reviews that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on the synthesis and presentation of research evidence, focusing on four key
questions.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and
relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on the
available evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key questions and answers: We found two reviews of instruments for critically appraising systematic reviews, several
studies of the importance of using extensive searches for reviews and determining when it is important to update
reviews, and consensus statements about the reporting of reviews that informed our answers to the following questions.
How should existing systematic reviews be critically appraised?
• Because preparing systematic reviews can take over a year and require capacity and resources, existing reviews should
be used when possible and updated, if needed.
• Standard criteria, such as A MeaSurement Tool to Assess Reviews (AMSTAR), should be used to critically appraise
existing systematic reviews, together with an assessment of the relevance of the review to the questions being asked.
When and how should WHO undertake or commission new reviews?
• Consideration should be given to undertaking or commissioning a new review whenever a relevant, up-to-date review
of good quality is not available.
• When time or resources are limited it may be necessary to undertake rapid assessments. The methods that are used
to do these assessments should be reported, including important limitations and uncertainties and explicit consideration
of the need and urgency of undertaking a full systematic review.
• Because WHO has limited capacity for undertaking systematic reviews, reviews will often need to be commissioned
when a new review is needed. Consideration should be given to establishing collaborating centres to undertake or
support this work, similar to what some national organisations have done.
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How should the findings of systematic reviews be summarised and presented to committees responsible
for making recommendations?
• Concise summaries (evidence tables) of the best available evidence for each important outcome, including benefits,
harms and costs, should be presented to the groups responsible for making recommendations. These should include an
assessment of the quality of the evidence and a summary of the findings for each outcome.
• The full systematic reviews, on which the summaries are based, should also be available to both those making
recommendations and users of the recommendations.
What additional information is needed to inform recommendations and how should this information be
synthesised with information about effects and presented to committees?
• Additional information that is needed to inform recommendations includes factors that might modify the expected
effects, need (prevalence, baseline risk or status), values (the relative importance of key outcomes), costs and the
availability of resources.
• Any assumptions that are made about values or other factors that may vary from setting to setting should be made
explicit.
• For global guidelines that are intended to inform decisions in different settings, consideration should be given to using 
a template to assist the synthesis of information specific to a setting with the global evidence of the effects of the relevant 
interventions.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the eighth of a series of 16
reviews that have been prepared as background for advice
from the WHO Advisory Committee on Health Research
to WHO on how to achieve this.
A summary of the best available research evidence is
essential, though not sufficient to inform recommenda-
tions. To reduce the risk of bias and errors that occur by
chance, and to facilitate critical appraisal of syntheses of
evidence, reviews should be systematic and should explic-
itly report the methods that were used [1]. However, sys-
tematic reviews require resources, take time, and may not
always be warranted or possible. Moreover, unnecessary
duplication of systematic reviews should be avoided,
given the large unmet need for systematic reviews of a
wide range of questions and the need to keep reviews up-
to-date [2,3].
The first step in considering the needs for systematic
reviews to inform recommendations is to critically
appraise existing reviews to determine if they provide an
adequate summary of the relevant evidence that is
needed, particularly evidence of the effects of the different
options (interventions) that are being considered. If they
do not, consideration must then be given to whether a
new review should be undertaken and how best to obtain
a new review. Once an adequate summary of the evidence
is available, consideration must be given to how best to
present that information to the group of people who will
consider that evidence, together with other evidence and
judgements, to develop recommendations. In addition,
consideration needs to be given to the additional infor-
mation that is needed and how that should be summa-
rised and presented.
In this paper we address the following questions:
￿ How should existing systematic reviews be critically
appraised and used?
￿ When and how should WHO undertake or commission
new reviews?
￿ How should the findings of systematic reviews be sum-
marised and presented to committees responsible for
making recommendations?
￿ What additional information is needed to inform rec-
ommendations and how should this information be syn-
thesised with information about effects and presented to
committees?
Related questions on priority setting for guidelines or rec-
ommendations and reporting of guidelines are addressed
in other papers in this series [4,5].
What WHO is doing now
Of 62 WHO documents that were indexed as guidelines in
2005, only two reported a systematic review and less than
40% included references [6]. Although it is possible that
systematic reviews are being used and this is not beingHealth Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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reported, this is unlikely. With some notable exceptions,
for the most part recommendations are currently being
made without adequate use of existing systematic reviews
and systematic reviews are rarely being undertaken or
commissioned by WHO committees that make recom-
mendations. However, the situation may be somewhat
better than what is reported in published guidelines.
When asked about the use of evidence of effects specifi-
cally in an interview study [7], many departments
reported using background documents. These were
reported to have been prepared in a variety of ways,
including as unpublished working papers, documents
similar to those used by the Scottish Intercollegiate Guide-
lines Network (SIGN), and documents prepared by the
participating experts. Only two departments reported
using systematic reviews specifically, while several others
reported using systematic reviews along with a range of
other documents. Others reported leaving the use of evi-
dence up to the experts, a lack of documentation, evidence
of effects not being relevant for some recommendations,
and using a mixture of "epidemiological data, trial data,
opinions based on logical reasoning (common sense) and
clinical experience."
No departments reported using concise summaries of
findings or "balance sheets" for the most important out-
comes (benefits, harms and costs) for the options that
were considered. WHO groups that develop recommen-
dations are, for the most part, composed of experts in a
particular content area and not supported by experts in
particular methodological areas (e.g. systematic reviews)
or by staff with particular technical skills (e.g. information
retrieval). Relatively little attention appears to have been
given to how best to help member states adapt global rec-
ommendations, taking account of local needs, values,
resources and conditions.
What other organisations are doing
In contrast, in a survey of 101 organisations that produce
clinical practice guidelines 95% of the 58 respondents
reported that they provide guideline panels with system-
atic reviews [8]. In another survey of 18 prominent organ-
isations that develop clinical practice guidelines, all but
one reported using systematic reviews [9].
The UK National Centre for Health and Clinical Excel-
lence (NICE), for example routinely undertakes system-
atic reviews to inform its guideline panels [10]. NICE has
seven professionally led National Collaborating Centres
to manage the development of clinical guidelines [11].
Each Centre has a range of skills and abilities, including
systematic reviewing. The Centres are responsible for
identifying the best and most relevant evidence available.
They write the first consultation draft of a guideline over a
period of 12 to 18 months. NICE reviews are available in
the full version of its guidelines.
Other organisations that produce guidelines sometimes
use existing systematic reviews, sometimes prepare their
own systematic reviews, and sometimes commission
reviews. The U.S. Preventive Services Task Force, for exam-
ple, commissions systematic reviews from Evidence-based
Practice Centers (EPCs) for updates of its guidelines [12].
The Agency for Healthcare Research and Quality (AHRQ)
has contracts with 13 EPCs from which it commissions
systematic reviews. AHRQ does not produce guidelines,
but stakeholder organisations that request the reviews
may produce guidelines. Other health technology assess-
ment (HTA) agencies, which may or may not produce
guidelines, have staff that undertake reviews, convene
expert groups that undertake reviews together with sup-
port from staff, or commission systematic reviews [13].
Systematic reviews of the effects of interventions are a
major focus for most organisations that develop guide-
lines. Because most organisations develop recommenda-
tions for a specific country or setting, they are able to take
into account additional information relevant to the spe-
cific context for which the recommendations are
intended, including factors that might affect the applica-
bility of the evidence in specific settings, need (preva-
lence, baseline risk or status), values, costs and the
availability of resources.
Methods
The methods used to prepare this review are described in
the introduction to this series [14]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We did not conduct a full sys-
tematic review. We searched PubMed and three databases
of methodological studies (the Cochrane Methodology
Register [15], the US National Guideline Clearinghouse
[16], and the Guidelines International Network [17]) for
existing systematic reviews and relevant methodological
research that address these questions. The answers to the
questions are our conclusions based on the available evi-
dence, consideration of what WHO and other organisa-
tions are doing, and logical arguments.
For this review we knew of two previous systematic
reviews of instruments for critically appraising systematic
reviews through personal contacts [18,19], and studies of
how to present the results of systematic reviews to policy
makers [20], the general public [21], and users of
Cochrane reviews [22]. We used these studies and their
reference lists to identify related articles in PubMed. We
searched the Cochrane Methodology Register using the
key word 'Presentation of reviews: General' and weHealth Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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checked the reference lists of the reports that we retrieved.
We searched for literature on priority setting for guide-
lines and health technology assessments for another
report [4]. In addition, we searched broadly for literature
on commissioning systematic reviews in PubMed (com-
missioning systematic reviews) and using Google ("com-
missioning systematic reviews" and "updating systematic
reviews") and in the Cochrane Methodology Register
using the terms 'commissioning' and 'updating systematic
reviews'. The searches were conducted in March 2006.
Findings
How should existing systematic reviews be critically 
appraised?
The first of two reviews of different instruments for criti-
cally appraising systematic reviews found 20 systems con-
cerned with the appraisal of systematic reviews or meta-
analyses, including one scale, 10 checklists, and nine
guidance documents [18]. The authors identified seven
key domains that they considered important to appraise:
study question, search strategy, inclusion and exclusion
criteria, data abstraction, study quality, data synthesis and
analysis, and funding or sponsorship. One checklist fully
addressed all seven domains [23]. A second checklist also
addressed all seven domains but merited only a "Partial"
score for study question and study quality [24]. Two addi-
tional checklists and the one scale addressed six of the
seven domains [25-27]. These latter two checklists
excluded funding; the scale omitted data abstraction and
had a "Partial" score for search strategy. The authors con-
cluded that based on coverage of the seven domains that
they considered key, these five systems (four checklists
and one scale) represented "best practice" (i.e. were the
best available instruments) for appraising systematic
reviews. Although they considered other aspects of the
systems, such as the methods used to select items and
inter-rater reliability, they did not take these factors into
consideration in their selection of these five systems, nor
did they consider the suitability of the different systems
for specific purposes.
The second review used a detailed process to evaluate and
select a system and expanded the work by AHRQ up until
the year 2005 [19]. They identified approximately 240
quality assessment instruments for systematic reviews,
randomized controlled trials and observational studies as
well as nearly 50 evidence grading systems. The instru-
ments and systems identified were evaluated by type of
study using the AHRQ evaluation grids from the first
review, and considering descriptive items for most poten-
tial instruments and systems. The highest scoring instru-
ments and systems from each grid represented the
proposed selections. The proposed selections were then
sent to the same experts that were contacted to review and
provide comment during the initial expert consultation.
Based on the second expert consultation, the AMSTAR
2005 was selected as the best instrument for appraising
systematic reviews (Table 1). A description of the ration-
ale for selecting that instrument is not available.
When and how should WHO undertake or commission new 
reviews?
There is wide agreement that guidelines should be
informed by systematic reviews of the best available evi-
dence among organisations that develop clinical practice
guidelines and, increasingly, among organisations that
develop guidance for population interventions (public
health, health promotion, health systems and social inter-
ventions) [8,9,28-34]. Thus, priorities for systematic
reviews are set, to some extent, when a decision is first
made to develop recommendations. We reviewed the
methodological literature relevant to priority setting for
guidelines and health technology assessments, which
overlaps largely with priority setting for systematic
reviews, in our review on setting priorities for developing
recommendations [4]. Additional questions related to
undertaking or commissioning new reviews include: If
there is a systematic review is it of good enough quality
and recent enough that a new review is unlikely to be
needed? Are there sufficient time and resources to com-
mission or undertake a new review, if one is needed? If
there is time, resources and a need for a new review, what
is the best approach to getting the work done?
The first of these questions can be answered by consider-
ing the criteria discussed above and the likelihood of
whether new research is likely to have been completed.
Under some circumstances, it may not be warranted or
possible to undertake or commission a systematic review
even if there is not a previous systematic review; for exam-
ple, for emerging diseases when it is known that the avail-
able evidence is sparse and when decisions must be made
urgently.
We address which evidence should be used to address dif-
ferent types of questions in another paper in this series
[35]. As we suggest in that paper, there is a cut-off point
beyond which broadening the types of studies that are
included requires a substantial investment of effort that
will not yield additional information that usefully
informs decisions. Similarly, there is a cut-off point
beyond which more extensive searches are unlikely to
yield additional useful studies.
An assessment of 159 systematic reviews with comprehen-
sive literature searches found that the importance of trials
that are difficult to locate may vary, but that generally in
situations where resources are limited, thorough quality
assessments should take precedence over extensive litera-
ture searches and translations of articles [36,37]. Consist-Health Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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Table 1: A MeaSurement Tool to Assess Reviews (AMSTAR), 2005 (from COMPUS [19])
1. Was an 'a priori' design provided?
The research question and inclusion criteria should be established before the conduct of the review.
Yes
No
Can't answer
Not applicable
2. Were there duplicate study selection and data extraction?
There should be at least two independent data extractors and the consensus procedure for disagreements should be reported.
Yes
No
Can't answer
Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases (e.g., Central, EPOC, and MEDLINE). Key words 
and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting 
current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies 
found.
Yes
No
Can't answer
Not applicable
4. Was the status of publication (i.e., grey literature) used as an exclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they 
excluded any reports (from the systematic review), based on their publication status.
Yes
No
Can't answer
Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
Yes
No
Can't answer
Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges 
of characteristics in all the studies analyzed (e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases) 
should be reported.
YesHealth Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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No
Can't answer
Not applicable
7. Was the scientific quality of the included studies assessed and reported?
'A priori' methods of assessment should be reported (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, 
placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
Yes
No
Can't answer
Not applicable
8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly 
stated in formulating recommendations.
Yes
No
Can't answer
Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess the homogeneity (i.e., Chi-squared test for 
homogeneity, I2). If heterogeneity exists, random effects model should be used and/or the clinical appropriateness of combining should be taken 
into consideration (i.e., is it sensible to combine?).
Yes
No
Can't answer
Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot) and statistical tests (e.g., Egger regression test).
Yes
No
Can't answer
Not applicable
11. Was the conflict of interest stated?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Yes
No
Can't answer
Not applicable
Source: AMSTAR 2005 (Beverley Shea, CIET, Institute of Population Health, Ottawa: personal communication, 2005 Oct)
Table 1: A MeaSurement Tool to Assess Reviews (AMSTAR), 2005 (from COMPUS [19]) (Continued)Health Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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ent with this, another assessment of Cochrane reviews
found that additional database searching beyond the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) retrieved only a small percentage of extra trials, and
that contacting authors and manufacturers to find unpub-
lished trials appeared to be a more effective method of
obtaining additional better quality trials [38].
Similarly, a third assessment of 20 Technology Assess-
ment Reports by NICE found that a more selective
approach to database searching would suffice in most
cases and would save resources, whereas searching other
sources, including contact with experts and checking ref-
erence lists, appeared to be a more productive way of
identifying further studies [39]. Searching additional data-
bases beyond the Cochrane Library, MEDLINE, EMBASE
and SCI, plus BIOSIS limited to meeting abstracts only,
was seldom found to be effective in retrieving additional
studies for inclusion in the clinical and cost-effectiveness
sections of Technology Assessment Reports (apart from
reviews of cancer therapies, where a search of the ASCO
database was recommended).
Information retrieval for systematic reviews for public
health and other non-clinical interventions may be more
elusive than retrieval for reviews in clinical medicine, due
to the interdisciplinary nature of the research, use of
research designs other than randomised trials, and limita-
tions of what and how the research is indexed. While it
may be important to consider other databases, strategies
other than database searching are likely to be important
[40,41]. Moreover, database searching in public health
and other non-clinical areas may require specialised skills
due to technical demands of the databases to be searched,
lack of standardization of the vocabulary, and the relative
scarcity of rigorous evaluations [42]. Information retrieval
specialists may require a broad exposure to databases, the
grey literature and the terminology that is used.
Several investigators have addressed the question of when
a review or guideline needs updating [37,43-47]. French
and colleagues found that of a sample of 254 updated
Cochrane reviews 23 (9%) had a change in conclusion
[43]. Another survey of Cochrane reviews found that of
104 updated reviews in the first half of 2003, 77%
included no new data or data insufficient to influence the
conclusion. In 16% new data had some impact on conclu-
sions without major change, and in only 5% new data
resulted in major changes in conclusions [44].
Johnston and colleagues, on the other hand, found that
an updating strategy for cancer practice guidelines found
80 pieces of new evidence over a one-year period relating
to 17 of 20 guidelines [45]. On average four pieces of new
evidence were found per guideline, but there was consid-
erable variation across the guidelines. Of the 80 pieces, 19
contributed to modifications of clinical recommenda-
tions in six practice guidelines, whereas the remaining evi-
dence supported the original recommendations. In this
case the updating process was resource intensive, but
yielded important findings. However, it was possible to
reduce the scope of the sources searched routinely to
MEDLINE, the Cochrane Library and meeting proceed-
ings. Another review of 17 guidelines published by AHRQ
found that for seven guidelines new evidence and expert
judgement indicated an update was needed, six were
found to be in need of a minor update, three were consid-
ered still valid, and no conclusion was drawn for one [47].
The authors found that no more than 90% of the guide-
lines were still valid after 3.6 years and they estimated that
about half the guidelines were outdated in 5.8 years. They
concluded that guidelines should be reassessed every
three years.
Comprehensive reviews are time-consuming. Many
health technology assessment (HTA) agencies have estab-
lished rapid assessment processes, particularly for new
technologies [48-51]. There is no common definition of
"rapid assessment" and there is variation in the scope,
methods and time to complete assessments. While the
concept is intuitively sound, there is little empirical evi-
dence comparing alternative methods or comparing rapid
assessments with more comprehensive methods. Milne
and colleagues have described a range of HTA responses
available in the UK, including 2–3 page assessments that
take six weeks, rapid systematic reviews that take 8–10
weeks, technology assessment reviews that take six
months, Cochrane reviews, and full HTA reports that take
3 years [52]. They identify three factors that determine the
HTA response: what decision-makers want, including the
time scale for decision making; the characteristics of the
technology, including the importance of the uncertainty,
the importance of the potential benefits, the rate of diffu-
sion, and how much is already known from previous
assessments; and the resources available for an assess-
ment.
We did not find any evaluations of alternative methods
for commissioning reviews or of comparisons between
commissioning reviews and doing them in house. A sur-
vey of people preparing Cochrane reviews in Australia
(with a response rate of 92/112) found that the most crit-
ical barriers to completion of a Cochrane review were lack
of time (80%), lack of financial support (36%), method-
ological problems (23%) and problems with group
dynamics (10%) [53].Health Research Policy and Systems 2006, 4:20 http://www.health-policy-systems.com/content/4/1/20
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How should the findings of systematic reviews be 
summarised and presented to committees responsible for 
making recommendations?
The Conference on Guideline Standardization (COGS)
developed an 18-item checklist for the reporting of guide-
lines [29]. The checklist includes the method for synthe-
sizing evidence (how evidence was used to create
recommendations, e.g., evidence tables, meta-analysis,
decision analysis) and the recommendation grading crite-
ria (the criteria used to rate the quality of evidence that
supports the recommendations and the system for
describing the strength of the recommendations).
The GRADE Working Group recommends the use of evi-
dence profiles including detailed descriptions of the
judgements used to assess the quality of evidence for each
important outcome and a summary of the findings for
each important outcome [54,55]. More recently the
Cochrane Collaboration has developed summary of find-
ings tables, based in part on GRADE evidence profiles
[22,56].
All of these methods of presenting evidence to decision
makers are based on consultations informed by evidence,
such as comparisons of different ways of presenting evi-
dence. We did not find comparisons of different ways of
presenting evidence to groups developing recommenda-
tions.
In addition to summaries of the main findings, such as
evidence profiles, the full systematic reviews should be
available to both those making recommendations and to
users of the recommendations [29]. These full systematic
reviews should adhere to standards such as those recom-
mended in the QUOROM statement [57].
What additional information is needed to inform 
recommendations and how should this information be 
synthesised with information about effects and presented 
to committees?
Although there are a number of descriptive papers and
guidelines for what additional information is needed in
addition to systematic reviews of the effects of the options
that are being considered, we did not find comparisons of
alternative ways of synthesising this information and pre-
senting it to groups making recommendations. As dis-
cussed in another article in this series [58], additional
information that needs to be considered in a recommen-
dation includes factors that might modify the expected
effects, need (prevalence, baseline risk or status), values
[59], costs and the availability of resources.
Methods of integrating this additional information and
judgements include formal and informal consensus meth-
ods [60,61], decision analyses, and economic analyses
[62,63]. Because factors such as modifying factors, needs
and the availability of resources can vary greatly from set-
ting to setting, methods for incorporating this informa-
tion in global guidelines are particularly challenging. We
did not find any evaluations of methods for addressing
these challenges.
Discussion
There is broad agreement on the need for systematic
reviews to inform recommendations and on criteria for
critically appraising systematic reviews. Several criteria
have been identified that need to be considered when
deciding whether a new systematic review is needed,
including the needs of decision makers, the nature of the
problem and the relevant interventions, and the availabil-
ity of resources.
The available evidence suggests that, generally, in situa-
tions where time or resources are limited, thorough qual-
ity assessments should likely take precedence over
extensive literature searches. When a full systematic
review is not undertaken, for example because of the need
for a rapid response, explicit consideration should be
given to the need and urgency of undertaking a full sys-
tematic review and putting in place appropriate mecha-
nisms for timely updating of the recommendations.
The frequency with which reviews or guidelines need to be
updated is likely to vary, but as a rough rule of thumb,
based in part on a study of clinical practice guidelines, the
need for updating should be considered routinely after
three years and more often for areas that are developing
rapidly.
Further work
Both the Agency for Healthcare Research and Quality and
the Canadian Coordinating Office for Health Technology
Assessment have funded projects on updating systematic
reviews [64,65]. These reports should help to fill in some
of the gaps in this review regarding when and how to
undertake or commission an update of a review. Further
work is needed on several of the other questions asked in
this review, including evaluation of methods for rapid
assessments, how best to present evidence to groups mak-
ing recommendations and, importantly for WHO, how
best to take into consideration information that varies
from setting to setting when making global recommenda-
tions.
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